Matinas BioPharma says Vascepa label expansion is 'ideal for the [Omega 3] class to kick off'

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive he's pleased the FDA is giving 'an early holiday gift' in the form of its approval for Amarin Corporation's (NASDAQ:AMRN) fish oil-derived drug Vascepa, now approved to prevent heart attacks and strokes in people who are at high cardiovascular risk.

Jabbour says the Vascepa label expansion is 'ideal for the [Omega 3] class to kick off,' and beneficial to patients, giving them greater access to a drug that can fight cardiovascular disease.

class